Skip Navigation
Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
AHRQ Home | Questions? | Contact Us | Site Map | What's New | Browse | Información en español | E-mail UpdatesE-mail Updates
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Off-Label Use of Atypical Antipsychotics: An Update

Slides: 1–12 of 47
Add to tray Remove from tray

Off-Label Use of Atypical Antipsychotics: An Update

Add to tray Remove from tray

Outline of Material

Keywords: antipsychotics | atypical antipsychotics | off-label | second generation
Add to tray Remove from tray

Introduction to Atypical Antipsychotics (1 of 4)

Keywords: antipsychotics | atypical antipsychotics | off-label | second generation
Add to tray Remove from tray

Introduction to Atypical Antipsychotics (2 of 4)

Keywords: aripiprazole | asenapine | atypical antipsychotics | clozapine | iloperidone | off-label | olanzapine | paliperidone | quetiapine | risperidone | second generation | ziprasidone | antipsychotics
Add to tray Remove from tray

Introduction to Atypical Antipsychotics (3 of 4)

Keywords: aripiprazole | atypical antipsychotics | autism | autism spectrum disorders | bipolar | major depressive disorder | MDD | off-label | olanzapine | quetiapine | risperidone | second generation | antipsychotics
Add to tray Remove from tray

Introduction to Atypical Antipsychotics (4 of 4)

Keywords: antipsychotics | atypical antipsychotics | off-label | second generation
Add to tray Remove from tray

Agency for Healthcare Research and Quality (AHRQ) Comparative Effectiveness Review (CER) Development

Keywords: comparative effectiveness review | systematic review
Add to tray Remove from tray

Rating the Strength of Evidence From the Comparative Effectiveness Review

Keywords: comparative effectiveness | GRADE | strength of evidence | comparative effectiveness review
Add to tray Remove from tray

Clinical Questions Addressed by the Comparative Effectiveness Review (1 of 2)

Keywords: antipsychotics | atypical antipsychotics | off-label | second generation | utilization | comparative effectiveness | efficacy
Add to tray Remove from tray

Clinical Questions Addressed by the Comparative Effectiveness Review (2 of 2)

Keywords: antipsychotics | atypical antipsychotics | off-label | second generation | adverse effects
Add to tray Remove from tray

Clinically Significant Outcomes of Interest in the Comparative Effectiveness Review (1 of 2)

Keywords: assessment BEHAVE-AD | atypical antipsychotics | BMI | BPRS | dementia | eating disorders | generalized anxiety disorder | HAM-A | HAM-D | MADRS | major depressive disorder | MDD | NPI | obsessive-compulsive disorder | OCD | off-label | second generation | YBOCS | antipsychotics
Add to tray Remove from tray

Clinically Significant Outcomes of Interest in the Comparative Effectiveness Review (2 of 2)

Keywords: antipsychotics | atypical antipsychotics | off-label | second generation | SCL-90-R | CGI-BPD | HAM-A | HAM-D | MADRS | BPRS | PANSS | CAPS | CCQ | ASI | YGTS | CGI-I | personality disorder | PTSD | post-traumatic stress disorder | substance abuse | Tourette’s | insomnia
Pages: [1] 2 3 4 Next
 
 
 
 
www.ahrq.gov AHRQ Home | Questions? | Contact AHRQ | Site Map | Accessibility | Privacy Policy | Freedom of Information Act | Disclaimers
U.S. Department of Health & Human Services | The White House | USA.gov: The U.S. Government's Official Web Portal

Agency for Healthcare Research and Quality • 540 Gaither Road Rockville, MD 20850 • Telephone: (301) 427-1364